Mammo Responsibility Ups Screening; Opioids for Cancer Pain? Ignored Signs of CRC

Women who scheduled their own mammograms were more likely to complete the screening process. (Penn Medicine, American Journal of Preventive Medicine)

With the blessings of the EU and Spanish health authorities, cancer specialists at a Barcelona hospital cooked up their own CAR T-cell therapy, which costs a third of the marketed brands. (STAT)

Sanofi announced it will terminate clinical development of the antibody-drug conjugate tusamitamab ravtansine following a negative outcome in a trial of second-line treatment for non-small cell lung cancer.

A trial of the radiopharmaceutical 177Lu-PNT2002 in advanced prostate cancer met the primary endpoint of progression-free survival, but showed an early survival trend favoring the control group, Lantheus and POINT Biopharma announced.

North Carolina has sued HCA Healthcare, alleging the for-profit system failed to keep promises to maintain consistent and high-quality oncology and emergency services following the 2019 acquisition of Mission Health System in Asheville.

The value of opioid analgesics for cancer-related pain requires reappraisal, given “the limited quality and quantity of research,” according to authors of a review. (CA: A Cancer Journal for Clinicians)

Colorectal cancer (CRC) screening is more effective than previously recognized, according to a reanalysis of clinical trial data. (MIT News)

People who developed CRC in their 20s and 30s share their experiences and the warning signs they ignored. (NBC News)

New insights into the continuing increase in endometrial cancer incidence and mortality, which disproportionately affects Black women. (Memorial Sloan Kettering Cancer Center)

The combination of a cancer vaccine and an immune checkpoint inhibitor reduced the risk of melanoma recurrence or death by 49% at 3 years. (CNBC)

Three of the first six patients with advanced melanoma that progressed on immune checkpoint inhibition responded to an investigational tumor-infiltrating lymphocyte cellular therapy and all six had disease control, Obsidian Therapeutics announced.

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow

Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests

A new study suggests that an older GLP-1 drug may help protect the brains of people with early Alzheimer’s disease, supporting the case for further

July 30, 2024

Esketamine after childbirth cuts risk of postnatal depression by three-quarters

Low-dose esketamine administered post-labor significantly reduced depressive symptoms in women with prenatal depression within 42 days, despite an increase in short-lived neuropsychiatric side effects.

April 15, 2024

Study reveals anesthetic injections as biggest stress factor in teen dental patients

Children are very stressed by anesthetics injected into the mouth before tooth extraction, in connection with orthodontic treatment.

June 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.